Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Oct 13, 2022 (4 years ago)

Betaxolol Ophthalmic Solution

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations:

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Betaxolol Ophthalmic Solution, USP 0.5%, (Betaxolol HCl 5.6 mg/mL), 5 mL per bottle, Sterile, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. NDC: 17478-705-10

Affected NDC 17478-0705-10

Compare with the code on your package — it is the most precise check available.

Drug: Betaxolol Category: Eye Drops & Ophthalmic

Recalling firm
Akorn, Inc.
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0135-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Betaxolol recalls

See all
Class I · High risk

Betaxolol Tablets

Presence of Foreign Tablets/Capsules: There is a potential presence of oxycodone HCl tablets, USP 5 mg in bottles.

Terminated Particulate / foreign matter KVK-Tech, Inc. NDC 10702-013-01 D-0049-2024
Class II · Moderate risk

Betaxolol Ophthalmic Solution

Microbial Contamination of Sterile Products: Confirmed sterility failure identified during stability testing at the 12-month time point.

Terminated Microbial contamination Akorn, Inc. NDC 17478-705-11 D-0004-2022

Other recalls by Akorn, Inc.

All 2022 recalls